DOP2016000220A - PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. - Google Patents

PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.

Info

Publication number
DOP2016000220A
DOP2016000220A DO2016000220A DO2016000220A DOP2016000220A DO P2016000220 A DOP2016000220 A DO P2016000220A DO 2016000220 A DO2016000220 A DO 2016000220A DO 2016000220 A DO2016000220 A DO 2016000220A DO P2016000220 A DOP2016000220 A DO P2016000220A
Authority
DO
Dominican Republic
Prior art keywords
tatk
compositions
formulations
cdkl5 fusion
fusion proteins
Prior art date
Application number
DO2016000220A
Other languages
English (en)
Spanish (es)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater filed Critical Univ Bologna Alma Mater
Publication of DOP2016000220A publication Critical patent/DOP2016000220A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737C-reactive protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022Cyclin-dependent kinase (2.7.11.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/405Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
DO2016000220A 2014-02-28 2016-08-23 PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. DOP2016000220A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
DOP2016000220A true DOP2016000220A (es) 2016-12-15

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000220A DOP2016000220A (es) 2014-02-28 2016-08-23 PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3608334B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3608334T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3608334T (enExample)
MX (2) MX2016011167A (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689B1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS59344B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT201900504T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
US20200299654A1 (en) * 2017-11-30 2020-09-24 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
EP4073231A4 (en) * 2019-10-30 2024-06-05 Amicus Therapeutics, Inc. RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND METHODS OF PRODUCTION
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
IL303239A (en) 2020-12-01 2023-07-01 Univ Pennsylvania Compositions and their uses for the treatment of Engelmann syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632444A1 (en) * 2010-10-25 2013-09-04 Université d'Aix-Marseille TREATMENT OF MeCP2-ASSOCIATED DISORDERS
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso

Also Published As

Publication number Publication date
MX2016011167A (es) 2017-04-06
SI3110837T1 (sl) 2019-12-31
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
JP2020062022A (ja) 2020-04-23
KR20170002372A (ko) 2017-01-06
IL247481B (en) 2020-07-30
JP6896050B2 (ja) 2021-06-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
EA201691691A1 (ru) 2017-05-31
JP6629747B2 (ja) 2020-01-15
DK3110837T3 (da) 2019-09-16
ZA201906304B (en) 2022-03-30
DK3608334T3 (da) 2021-08-23
EA202190727A2 (ru) 2021-07-30
EA038000B1 (ru) 2021-06-22
BR112016019868A2 (pt) 2017-10-17
EP3608334B1 (en) 2021-05-19
CL2016002142A1 (es) 2017-09-08
RS62244B1 (sr) 2021-09-30
KR102307276B1 (ko) 2021-09-30
WO2015128746A3 (en) 2015-11-26
LT3110837T (lt) 2019-10-10
CN106255706A (zh) 2016-12-21
PH12016501689A1 (en) 2016-10-03
NI201600127A (es) 2017-03-13
US20180327725A1 (en) 2018-11-15
NZ723371A (en) 2023-11-24
AU2019219743A1 (en) 2019-09-19
ZA201606655B (en) 2020-05-27
HUE055282T2 (hu) 2021-11-29
EP3110837B1 (en) 2019-06-12
CY1124727T1 (el) 2022-07-22
PE20161406A1 (es) 2017-01-14
RS59344B1 (sr) 2019-10-31
SI3608334T1 (sl) 2021-11-30
AU2019219743B2 (en) 2020-10-29
CR20160392A (es) 2017-06-12
US9944910B2 (en) 2018-04-17
CA2940401C (en) 2022-11-29
AU2015221860A1 (en) 2016-09-08
US20150247134A1 (en) 2015-09-03
CA2940401A1 (en) 2015-09-03
BR112016019868B1 (pt) 2023-11-28
SMT202100478T1 (it) 2021-09-14
PT3608334T (pt) 2021-08-25
US20160194617A1 (en) 2016-07-07
SMT201900504T1 (it) 2019-11-13
AU2015221860B2 (en) 2019-09-12
EP3608334A1 (en) 2020-02-12
US20200199549A1 (en) 2020-06-25
EP3110837A2 (en) 2017-01-04
WO2015128746A2 (en) 2015-09-03
PL3110837T3 (pl) 2020-04-30
SV2016005264A (es) 2017-02-15
PH12016501689B1 (en) 2016-10-03
US9290746B2 (en) 2016-03-22
SG11201606863YA (en) 2016-09-29
PT3110837T (pt) 2019-09-12
HUE045393T2 (hu) 2019-12-30
PL3608334T3 (pl) 2021-11-22
HRP20191511T1 (hr) 2019-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX2020001223A (es) 2022-05-31
ES2745335T3 (es) 2020-02-28
US10584318B2 (en) 2020-03-10
US10907138B2 (en) 2021-02-02
ES2885245T3 (es) 2021-12-13
IL275435A (en) 2020-08-31
JP2017507655A (ja) 2017-03-23
MX392778B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CL2024004045A1 (es) Medios y método para preparar vectores virales y usos de los mismos
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
MX2017015046A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
BR112019012343A2 (pt) anticorpos il-11ra
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112019012342A2 (pt) anticorpos il-11
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
MX2019004690A (es) Constructos de anticuerpos.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
BR112018002150A2 (pt) proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2022014781A (es) Formulaciones de anticuerpos anti-pdl1.
MX2016017025A (es) Formulaciones de proteinas.
MX2018003445A (es) Expresion de proteinas que contienen fc.
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
EP3888671A3 (en) Protein formulations
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas
MX2019006354A (es) Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso.